Portal:Viruses

From Wikipedia, the free encyclopedia

The Viruses Portal
Welcome!

The capsid of SV40, an icosahedral virus
The capsid of SV40, an icosahedral virus

Viruses are small infectious agents that can replicate only inside the living cells of an organism. Viruses infect all forms of life, including animals, plants, fungi, bacteria and archaea. They are found in almost every ecosystem on Earth and are the most abundant type of biological entity, with millions of different types, although only about 6,000 viruses have been described in detail. Some viruses cause disease in humans, and others are responsible for economically important diseases of livestock and crops.

Virus particles (known as virions) consist of genetic material, which can be either DNA or RNA, wrapped in a protein coat called the capsid; some viruses also have an outer lipid envelope. The capsid can take simple helical or icosahedral forms, or more complex structures. The average virus is about 1/100 the size of the average bacterium, and most are too small to be seen directly with an optical microscope.

The origins of viruses are unclear: some may have evolved from plasmids, others from bacteria. Viruses are sometimes considered to be a life form, because they carry genetic material, reproduce and evolve through natural selection. However they lack key characteristics (such as cell structure) that are generally considered necessary to count as life. Because they possess some but not all such qualities, viruses have been described as "organisms at the edge of life".

Selected disease

Shingles rash on the chest
Shingles rash on the chest

Shingles, or herpes zoster, is a painful skin rash with blisters that, characteristically, occurs in a stripe limited to just one side of the body. The rash usually heals within 2–5 weeks, but around one in five people experience residual nerve pain for months or years.

Shingles is caused by varicella zoster virus (VZV), an alpha-herpesvirus. Initial VZV infection usually occurs in childhood causing chickenpox. After this resolves, the virus is not eliminated from the body, but remains latent in the nerve cell bodies of the dorsal root or trigeminal ganglia, without causing symptoms. Years or decades later, shingles occurs when virions in a single ganglion reactivate, travel down nerve fibres and infect the skin around the nerve. The shingles rash is restricted to the area of skin supplied by a single spinal nerve, termed the dermatome. Exactly how VZV remains latent in the body, and subsequently reactivates, is unclear.

Around a third of the population will develop shingles. Repeated episodes are rare. In the United States, about half the cases occur in people aged 50 years or older. Vaccination at least halves the risk, and prompt treatment with aciclovir or related antiviral drugs can reduce the severity and duration of the rash.

Selected image

Egyptian stele believed to show a poliomyelitis survivor

This 18th Dynasty Egyptian stele, believed to show a priest with poliomyelitis-associated deformity, is one of the earliest records of a viral disease.

Credit: Unknown (1580–1350 BC)

In the news

Map showing the prevalence of SARS-CoV-2 cases; black: highest prevalence; dark red to pink: decreasing prevalence; grey: no recorded cases or no data
Map showing the prevalence of SARS-CoV-2 cases; black: highest prevalence; dark red to pink: decreasing prevalence; grey: no recorded cases or no data

26 February: In the ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 110 million confirmed cases, including 2.5 million deaths, have been documented globally since the outbreak began in December 2019. WHO

18 February: Seven asymptomatic cases of avian influenza A subtype H5N8, the first documented H5N8 cases in humans, are reported in Astrakhan Oblast, Russia, after more than 100,0000 hens died on a poultry farm in December. WHO

14 February: Seven cases of Ebola virus disease are reported in Gouécké, south-east Guinea. WHO

7 February: A case of Ebola virus disease is detected in North Kivu Province of the Democratic Republic of the Congo. WHO

4 February: An outbreak of Rift Valley fever is ongoing in Kenya, with 32 human cases, including 11 deaths, since the outbreak started in November. WHO

21 November: The US Food and Drug Administration (FDA) gives emergency-use authorisation to casirivimab/imdevimab, a combination monoclonal antibody (mAb) therapy for non-hospitalised people twelve years and over with mild-to-moderate COVID-19, after granting emergency-use authorisation to the single mAb bamlanivimab earlier in the month. FDA 1, 2

18 November: The outbreak of Ebola virus disease in Équateur Province, Democratic Republic of the Congo, which started in June, has been declared over; a total of 130 cases were recorded, with 55 deaths. UN

Selected article

Plaque assay for herpes simplex virus

Virus quantification is necessary for viral vaccine production, and is used to manage people infected with HIV, hepatitis B and C, and cytomegalovirus. A wide range of traditional and modern methods are used. Plaque assays (pictured) infect a monolayer of host cells with dilutions of the virus and count the number of holes or plaques, where cells have lysed and infected their neighbours. For viruses that do not lyse their host cell, plaques of cells showing cytopathic effects can be counted or viral proteins can be immunostained with fluorescent-labelled antibodies. These methods quantify infectious virus, while others, such as electron microscopy, return a higher concentration because they count all virus particles, whether or not they are viable. Other assays, such as the haemagglutinin assay, quantify viral proteins.

Often slow and labour intensive, traditional methods have been complemented by modern technologies that greatly reduce quantification time, including quantitative polymerase chain reaction, flow cytometry, enzyme-linked immunosorbent assays and tunable resistive pulse sensing.

Selected outbreak

American soldiers with influenza H1N1 at a hospital ward at Camp Funston
American soldiers with influenza H1N1 at a hospital ward at Camp Funston

The 1918–20 influenza pandemic, the first of the two involving H1N1 influenza virus, was unusually deadly. It infected 500 million people across the entire globe, with a death toll of 50–100 million (3–5% of the world's population), making it one of the deadliest natural disasters of human history. It has also been implicated in the outbreak of encephalitis lethargica in the 1920s. Despite the nickname "Spanish flu", the pandemic's geographic origin is unknown.

Most influenza outbreaks disproportionately kill young, elderly or already weakened patients; in contrast this predominantly killed healthy young adults. Contemporary medical reports suggest that malnourishment, overcrowded medical facilities and poor hygiene promoted fatal bacterial pneumonia. Some research suggests that the virus might have killed through a cytokine storm, an overreaction of the body's immune system. This would mean the strong immune reactions of young adults resulted in a more severe disease than the weaker immune systems of children and older adults.

Selected quotation

Ed Rybicki

Recommended articles

Viruses & Subviral agents: bat virome • elephant endotheliotropic herpesvirus • HIV • introduction to viruses • Playa de Oro virus • poliovirus • prion • rotavirus • virus

Diseases: colony collapse disorder • common cold • croup • dengue fever • gastroenteritis • Guillain–Barré syndrome • hepatitis B • hepatitis C • hepatitis E • herpes simplex • HIV/AIDS • influenza • meningitis • myxomatosis • polio • pneumonia • shingles • smallpox

Epidemiology & Interventions: 2007 Bernard Matthews H5N1 outbreak • Coalition for Epidemic Preparedness Innovations • Disease X • 2009 flu pandemic • HIV/AIDS in Malawi • polio vaccine • Spanish flu • West African Ebola virus epidemic

Virus–Host interactions: antibody • host • immune system • parasitism • RNA interference

Methodology: metagenomics

Social & Media: And the Band Played On • Contagion • "Flu Season" • Frank's Cock • Race Against Time: Searching for Hope in AIDS-Ravaged Africa • social history of viruses • "Steve Burdick" • "The Time Is Now" • "What Lies Below"

People: Brownie Mary • Macfarlane Burnet • Bobbi Campbell • Aniru Conteh • people with hepatitis C • HIV-positive people • Bette Korber • Henrietta Lacks • Linda Laubenstein • Barbara McClintock • poliomyelitis survivors • Joseph Sonnabend • Eli Todd • Ryan White

Selected virus

Diagram of HIV structure

Human immunodeficiency virus (HIV) is a lentivirus, an RNA virus in the retrovirus family. Two types of HIV have been characterised: HIV-1 is the more virulent and is responsible for most infections worldwide; HIV-2 is mainly confined to West Africa. The genome consists of two copies of a single-stranded +RNA, which contains nine genes. The roughly spherical virus particle has a diameter of about 120 nm; it is enveloped and contains a conical capsid made of around 2,000 copies of the p24 protein. The envelope glycoprotein, a trimeric complex of gp120 and gp41, binds to CD4, the primary receptor on the host cell.

Transmission occurs by the transfer of bodily fluids including blood, semen, vaginal fluids and breast milk, in which the virus is present both as free virus particles and within infected immune cells. HIV infects key cells in the human immune system including CD4+ T helper cells, macrophages and dendritic cells. Infection leads to low levels of CD4+ T cells via several mechanisms, resulting in a progressive immunodeficiency disease known as AIDS.

Did you know?

Scanning electron micrograph showing SARS-CoV-2 (yellow)

Selected biography

Jonas Salk (1955)

Jonas Edward Salk (28 October 1914 – 23 June 1995) was an American medical researcher and virologist, best known for developing the first successful polio vaccine.

Unlike most other researchers, Salk focused on creating an inactivated or "killed" virus vaccine, for safety reasons. The vaccine he developed combines three strains of wild-type poliovirus, inactivated with formalin. The field trial that tested its safety and efficacy in 1954 was one of the largest carried out to date, with vaccine being administered to over 440,000 children. When the trial's success was announced, Salk was hailed as a miracle worker and national hero. A little over two years later, 100 million doses of the vaccine had been distributed throughout the US, with few reported adverse effects. An inactivated vaccine based on the Salk vaccine is the mainstay of polio control in many developed countries.

Salk also researched vaccines against influenza and HIV. In 1960, he founded the Salk Institute for Biological Studies research centre in La Jolla, California.

In this month

Crystalline form of zidovudine, viewed in polarised light

March 1990: Proposal for a database of all viruses, later the ICTVdB

3 March 2014: Discovery of Pithovirus sibericum, the largest known virus at 1.5 μm long by 0.5 μm in diameter

4 March 1918: First case reported in the 1918 influenza pandemic

10 March 1956: Francis Crick and James Watson proposed that small viruses have a protein shell consisting of a large number of identical subunits

10 March 1956: Donald Caspar published paper on the structure of tomato bushy stunt virus

13 March 2003: Enfuvirtide (T20) approved; first HIV fusion inhibitor, also first HIV entry inhibitor

20 March 1987: Antiretroviral drug AZT (pictured) became the first antiviral medication approved for use against HIV/AIDS

22 March 2014: First case reported in the West African Ebola outbreak, the most widespread so far

26 March 1953: Jonas Salk reported a successful test of an inactivated polio vaccine.

28 March 2003: Mimivirus shown to be a virus, then the largest known

Selected intervention

Ball-and-stick model of oseltamivir

Oseltamivir (also Tamiflu) is an oral antiviral drug against influenza (flu). It was the second inhibitor of the viral neuraminidase to be developed, after zanamivir, and the first to be taken as an oral tablet. It was originally synthesised from shikimic acid extracted from the star anise plant. Oseltamivir is a prodrug that requires metabolism in the liver to the active form, oseltamivir carboxylate. This binds at the active site of the neuraminidase enzyme, preventing it from cleaving sialic acid to release the virus particle from the host cell. Oseltamivir can reduce the duration of influenza symptoms by 0.5–1 days. Debate is ongoing about whether it also reduces the risk of complications, such as pneumonia. Nausea and vomiting are the main adverse events. Resistance to oseltamivir has been observed in some strains of influenza virus, especially H1N1 strains.

Subcategories

Topics

Things to do

WikiProjects & Portals

WikiProject Viruses
Related WikiProjects

MedicineMicrobiologyMolecular & Cellular BiologyVeterinary Medicine

Related Portals

Associated Wikimedia

The following Wikimedia Foundation sister projects provide more on this subject: